Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.06.22	Astellas Submits Fezolinetant New Drug Application to U.S. FDA (PR Newswire)
08.06.22	Astellas Celebrates the Opening of Its New Large-Scale Gene Therapy Manufacturing Facility in North Carolina (PR Newswire)
01.06.22	Astellas and GO Therapeutics Enter into Strategic Research and License Agreement to Develop Novel Antibodies for Immuno-Oncology (PR Newswire)
12.05.22	Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress (PR Newswire)
05.05.22	Astellas to Present 12-Week Data from Pivotal Phase 3 SKYLIGHT 1™ Trial of Fezolinetant in Oral Session at the American College of Obstetricians and Gynecologists Annual Meeting (PR Newswire)
27.04.22	Astellas Pharma FY21 Core Profit Decreases; Revenue Up 3.7% (RTTNews)
25.04.22	University Of Tokyo, Astellas Pharma Enter Second Phase Of Collaboration - Quick Facts (RTTNews)
25.04.22	University of Tokyo, Astellas Enter Second Phase of Strategic Partnership for Co-creation of Innovative New Medicines and Medical Solutions (PR Newswire)
13.04.22	European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
15.03.22	Astellas : Phase 3 Study Of Fezolinetant On VMS Associated With Menopause Did Not Show Efficacy (RTTNews)
15.03.22	Astellas Announces Topline 12-week Results from Phase 3 Study of Fezolinetant for the Nonhormonal Treatment of Vasomotor Symptoms in Women in Asia (PR Newswire)
07.03.22	Astellas Reports Positive Results From Phase 3 Study Of Fezolinetant On Vasomotor Symptoms (RTTNews)
07.03.22	Astellas Announces Topline Results from Long-Term Phase 3 Safety Study of Fezolinetant which Inform Future Regulatory Filings for the Treatment of Vasomotor Symptoms Associated with Menopause (PR Newswire)
28.02.22	Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
14.02.22	Astellas and Seagen Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy (PR Newswire)
08.02.22	Astellas Pharma Announces Positive Data From Study Of AT845 In Adults With Late-Onset Pompe Disease (RTTNews)
08.02.22	Astellas Announces Positive Safety Data from the FORTIS Study of AT845 in Adults with Late-Onset Pompe Disease (PR Newswire)
17.12.21	Astellas, Seagen Announce Positive CHMP Opinion For PADCEV - Quick Facts (RTTNews)
17.12.21	Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
14.12.21	Astellas and MBC BioLabs Announce Future Innovator Prize Winners - Helping Biotech Start-ups Accelerate Early Research Efforts (PR Newswire)
02.12.21	Astellas, Dyno Therapeutics To Develop AAV Gene Therapy Vectors For Skeletal And Cardiac Muscle (RTTNews)
02.12.21	Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle (PR Newswire)
01.12.21	Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia - from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting (PR Newswire)
03.11.21	Astellas and LabCentral Announce Future Innovator Prize Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science (PR Newswire)
12.10.21	Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer (PR Newswire)
27.09.21	Astellas Pharma, Seagen: Japan's MHLW Oks PADCEV For Advanced Urothelial Cancer (RTTNews)
27.09.21	Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer (PR Newswire)
22.09.21	Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting (PR Newswire)
21.09.21	Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts (PR Newswire)
18.09.21	Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study (PR Newswire)
14.09.21	Astellas Pharma Says Rare Neuromuscular Clinical Trial Participant Passed Away (RTTNews)
14.09.21	Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy (PR Newswire)
01.09.21	Astellas Pharma Halts Rare Neuromuscular Clinical Trial Due To Serious Adverse Event (RTTNews)
01.09.21	Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy (PR Newswire)
20.08.21	Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease (PR Newswire)
18.08.21	Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research (PR Newswire)
21.07.21	U.S. Food and Drug Administration Expands Indication for PROGRAF® for Prevention of Organ Rejection in Adult and Pediatric Lung Transplant Recipients (PR Newswire)
09.07.21	U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
25.06.21	Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease (PR Newswire)
08.06.21	New Research Reflects Astellas' Commitment to Acute Myeloid Leukemia at EHA 2021 Virtual Congress (PR Newswire)
04.05.21	Astellas: European Commission Approves Additional Indication For XTANDI - Quick Facts (RTTNews)
19.04.21	Seagen : FDA Accepts Two SBLA For PADCEV In Locally Advanced Or Metastatic Urothelial Cancer (RTTNews)
30.03.21	Astellas' Gilteritinib Meets Overall Survival Endpoint In Phase 3 Trial On Acute Myeloid Leukemia (RTTNews)
26.03.21	Astellas : FDA Approves Myrbetriq For Children With Neurogenic Detrusor Overactivity (RTTNews)
26.03.21	Astellas Gets Positive CHMP Opinion For XTANDI On Metastatic Hormone-Sensitive Prostate Cancer (RTTNews)
13.01.21	Actinium Pharma Announces Research Collaboration With Astellas - Quick Facts (RTTNews)
27.12.20	Audentes : FDA Lifts Clinical Hold On Trial Of AT132 For Treatment Of X-Linked Myotubular Myopathy (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Aktien Top/Flop

Meistgelesene Nachrichten